Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Monty has done more than anyone else here!
Thank you!
Novel botanical formulation (old Nicosan) for treating sickle cell disease - New Patent (20110300242) through Swami Nathan and Robert Swift
- It's the new Nicosan with an other solvent ph used for extraction (sodium bicarbonate ph 8-8,3)
- new formulation: 8 % of cells still sickled
- Nicosan: 18 % of cells still sickled
- Filed Date: 8. Jun. 2010
- Published Date: 8. Dec. 2011
http://www.freepatentsonline.com/20110300242.pdf
The road to commercialization in Africa: lessons
from developing the sickle-cell drug Niprisan - BMC International Health and Human Rights 13 December 2010
http://www.biomedcentral.com/content/pdf/1472-698x-10-s1-s11.pdf
Xechem Inc
379 Thornall Street # 9
Edison, NJ 08837-2226 map
Middlesex-Somerset, NJ Metro Area
Phone: (732) 247-3300
About:
Xechem Inc in Edison, NJ is a private company which is listed under chemists-analytical and consulting. Current estimates show this company has an annual revenue of Less than $500,000 and employs a staff of 50 to 99.
Robert Swift
Chairman
Xechem Inc
Edison, NJ
http://www.manta.com/c/mtwvnm1/xechem-inc
Hey Monty
Who is Swift contact person in Austria and what product?
Still here my friends, still here and never ever give up!
SNWT should offer KTM products!
http://www.ktm.com/
http://www.erzbergrodeo.at/en/erzbergrodeo/xvii
Judge Jack B. Schmetterer-Court Calendar
Tuesday, April 19, 2011
Updated 04/19/2011 @ 10:23:AM CST
08bk30512
This[339] XECHEM INC CH. 11
Status hearing
08bk30513
This[232] XECHEM INTERNATIONAL, INC. CH. 7
Post Conversion Status Hearing
08bk30512
This[338]
Orig[278] XECHEM INC CH. 11
Motion : Uncontested Motion to Vacate (related documents [273] Order Scheduling) Filed by Sara E Lorber on behalf of Ramesh Pandey.
08bk30513
This[230]
Orig[66] XECHEM INTERNATIONAL, INC. CH. 11
Objection to Claim : Objection to Claim(s) 41 Filed by Robert E Richards on behalf of The Official Committee of Unsecured Creditors.
08bk30513
This[230]
Orig[72] XECHEM INTERNATIONAL, INC. CH. 11
Objection to Claim : Objection to Claim(s) 41 Filed by Douglas S Draper on behalf of XECHEM International, Inc.
08bk30513
This[230]
Orig[67] XECHEM INTERNATIONAL, INC. CH. 11
Objection to Claim : Objection to Claim(s) 57 Filed by Robert E Richards on behalf of The Official Committee of Unsecured Creditors.
08bk30513
This[230]
Orig[68] XECHEM INTERNATIONAL, INC. CH. 11
Objection to Claim : Objection to Claim(s) 57 Filed by Douglas S Draper on behalf of XECHEM International, Inc.
10ap00065
This[83] XECHEM INC 08BK30512, OFFICIAL COMMITTEE OF UNSECURED CREDITORS V. SWIFT ET AL AP
Status Hearing Adversary case 10-00065. (02 (Other (e.g. other actions that would have been brought in state court if unrelated to bankruptcy))): Complaint by Official Committee of Unsecured Creditors against Robert Swift, Cosmid Corp. LLC. Fee Amount $250.Status hearing
10ap00065 This[84]
Orig[64] XECHEM INC 08BK30512, OFFICIAL COMMITTEE OF UNSECURED CREDITORS V. SWIFT ET AL AP
Motion : Emergency Motion to Withdraw as Attorney Filed by Kenneth A. Henry on behalf of Cosmid Corp. LLC, Robert Swift.
10ap00065
This[85]
Orig[70] XECHEM INC 08BK30512, OFFICIAL COMMITTEE OF UNSECURED CREDITORS V. SWIFT ET AL AP
Motion : Motion to Set Hearing Ruling on Motion to Withdraw. Filed by Kenneth A. Henry on behalf of Kenneth A. Henry.
08bk30512
This[349] XECHEM INC CH. 7
Notice of Motion and Application to Employ Colleen E. McManus and the law firm of Much Shelist Denenberg Ament & Rubenstein, P.C. as Attorneys Filed by Norman B Newman
Thanks Steve, GN!
I'm still here...4
That's true, my buddy.
Nigeria Pharmaceuticals and Healthcare Report Q2 2011
Date: Feb, 2011
Q211 has proved to be a difficult period for Nigeria’s Pharmaceutical market. In December 2010, leaked US embassy cables indicated that Pfizer, the world’s largest pharmaceutical manufacturer, had hired investigators to unearth evidence of corruption against the Nigerian attorney general. Action taken by the company was alleged to have stemmed from a desire to persuade him to drop legal action over a controversial drug trial involving the antibiotic Trovan (trovafloxacin) in 1996 for treating children with meningitis. The subsequent public outcry from these revelations has hurt Pfizer’s public image in Nigeria. This is likely to impact the company’s sales in the short term and slow the approval process for new products from multinational drugmakers.
Also in December, Edo State government began the construction of a modern hospital ward at Edo State Specialist hospital in Nigeria, while November 2010 saw construction begin for a multi-billion naira healthcare facility in Kano State, primarily paid for with the money from the 2009 Pfizer lawsuit settlement.
In January 2011, the Nigerian Medical Association (NMA)’s Ebonyi State chapter began an indefinite strike, saying the action was a result of the government’s refusal to pay the consolidated medical salary structure (CONMESS) to doctors. Physicians argue that an increase in wages is needed to stem physician emigration to developed countries. In November 2010, the governor of Nigeria's Niger State increased the wages of healthcare workers by 180% in an effort to retain more staff.
In December 2010, Karniyus Gamaniel, director of the Nigerian Institute of Pharmaceutical Research and Development (NIPRD), announced that production of the phytogenic (plant-derived) sickle cell disease (SCD) drug Nicosan (an ethanol/water extract of Piper guineense seeds, Pterocarpus osum stem, Eugenia caryophyllus fruit and Sorghum bicolor leaves) is to resume. The production and phase III trials of the drug were stopped when the government withdrew Xechem Pharmaceuticals Nigeria's production licence in 2009, following accusations of misuse of funds.
Over 200,000 children are born with SCD in sub-Saharan Africa every year and there are an estimated 4mn people in Nigeria with some form of the disease, according to AesRx, a company developing SCD treatment Aes-103 (5-hydroxymethyl-2-furfural). Currently, the main treatment for SCD is Droxia (hydroxyurea), which was approved in 1998. However, not all patients respond to this drug and some experience adverse effects, including myelosuppression (suppression of the body’s production of bone marrow). This lack of available drugs presents an opportunity to drugmakers, especially as the World Health Organization (WHO) has granted almost every SCD drug orphan status to help address the immediate healthcare need.
http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/drugs_biotechnology/nigeria_pharmaceuticals_n_healthcare_report_q2_2011.html
too funny tom88 :D
I know about Alverson and....but the next logical step is a reverse merger.
If there is nothing, why you are still here?
They are talking about news, merger, p&d, what else?
A lot of talking about TVLS on the boards.
That's maybe true tom8oes and thank you....
but I can't hear Arnold here and I'm an Austrian!
:) Thank you Elis!
?? http://ih.advfn.com/p.php?pid=trades&symbol=XKEMQ
silent buying but what's with the ? volume?
Thank you SteveKing!
That's true...we will see
This is only the beginning of our journey
Come down and relax, I'm from europe.
... said the boring pelican :D
It can't be W. M. A. because he must pump it back to more than 1$ to get out of the $troubles$. I hope to get more information soon...
I'm buying more!
Thank you jgervasi1!
We will see what happens
Hey Tom
Look for tvls!!
No news out there.
I hope we hear more when market is closed.
yeah but what's up?
+2100%
what's wrong here carlito??
we got the jackpot?
Thank you Monty, because I have forgotten our all best friend.
http://iretioniyide.com/ireti_achievement.html
http://www.facebook.com/pages/Ireti-Oniyide-For-Ogun-State-Governor-2011/141499625862046
I found this:
http://www.realpennies.com/otc/XKEMQ
Xechem International Inc. Presents at 21st Annual Financial Conference, Mar-01-2011
10/19/2010
Xechem International Inc. Presents at 21st Annual Financial Conference, Mar-01-2011 . Venue: The University Club, New York, NY 10019, United States.
Corruption in Nigeria
Nigeria: Minister of State for Health Too
Abdulkadir Badsha Mukhtar
25 January 2011
The Independent Corrupt Practices and Other Related Offences Commission (ICPC) is to arraign Minister of State for Health Alhaji Sulaiman Bello before the Adamawa State High Court in Yola over alleged N11.2 million bribe.
The minister is to be arraigned on January 31 on eight count charges among which is using his office to confer corrupt advantage on himself and others country to the section 19 of the ICPC Act 2000.
The minister, according to a charge sheet prepared by the ICPC, was alleged to have used his position as Resident Electoral Commissioner (REC) with the Independent National Electoral Commission (INEC) to solicit for and collect the sum of N11.2m as "hardship" allowance from Adamawa State governor during the April 2007 on general elections in the state contrary to and punishable under section 25 sub section (1) and(a) of the ICPC Act.
Bello was also alleged to have solicited the total sum in July 2007 from the Adamawa State governor but collected N750,000 out of money as hazard allowance thereby committed an offence contrary to and punishable under section 19 of the ICPC Act.
The minister was further alleged to have used his position as REC of Adamawa State to confer a corrupt advantage upon another public officer when he unlawfully solicited the sum of N11.2m from the governor and gave N500, 000.00 to one M.S Na'Allah, an official of INEC Adamawa State office, thereby committed an offence contrary to and punishable under section 19 of the ICPC Act.
In the charge sheet, Bello allegedly shared the sum of N250,000 each to Mallam Ibrahim Mamman, Alhaji A.A Gunjigu, Mr. Ambrose A. Umms, Mallam Umani Tanko and Refehatu M. Duku, all staff of INEC Adamawa State office, there by committing an offence contrary and punishable under section 19 of the ICPC Act
http://allafrica.com/stories/201101250599.html
Uncertainty clouds Minister’s stay in cabinet ahead of trial
News Jan 26, 2011 By VICTORIA OJEME
ABUJA—A cloud of uncertainty was yesterday hovering over the continued stay in the federal cabinet of the embattled Minister of State for Health, Alhaji Suleiman Bello, ahead of his expected trial for corruption by the Independent Corrupt Practices and other related offences Commission, ICPC.
The Presidency was non- committal on speculations concerning the fate of the embattled minister who himself has said that the unfolding development will be an unforgettable experience for the rest of his life.
The ICPC has meanwhile lined up a pack of witnesses to testify against Bello one of whom is expected to tell the trial court that there is no provision for hardship allowance in the entitlement for officers of the Independent National Electoral Commission, INEC, where Bello worked at the time of the offence in 2007.
Bello, according to findings made by the ICPC, requested and obtained N14.25 million as “Hardship Allowance” from the Adamawa State government while he served in the state as Resident Electoral Commissioner, REC. The request, according to the ICPC, was against laid down provisions.
According to the proof of evidence, in the charge sheet, FHC/YL/125C/2010, dated December 7, 2010, obtained by Vanguard, a former Director of ICPC Mrs. Eno Gamble, is expected to testify before the court and rebuff claims by the Minister that he had authority to solicit money from the state government.
In the proof of evidence against Sulieman, Gamble is expected to tell the court that, “hazard allowance is not part of the condition of service of staff in INEC and that the state office has no power to create any allowance from the governor or any agency of government or person.”
The former DFA, as gathered in response to enquiries from the ICPC, also dismissed Suileman’s claims that part of the said money was used to fund relocation of Adamawa INEC state office to its new building.
She is therefore expected to tell the court that, even though she could not confirm if funds were approved from the INEC headquarters for the relocation of the office, Sulieman ought to, “use the funds from routine overhead remitted to the state office from the headquarters on monthly basis.
“She will say that the State Accountant actually informed her that they used the said funds from main over head account for the relocation. She will testify that the fund remitted to the state is enough for the conduct of the elections because it was based on the submissions by the Operations Department,” the document stated.
Other witnesses, as learnt, include two members of the investigative panel, set up by the ICPC to probe the petition upon which the investigation against Bello was made.
The Minister has meanwhile claimed that he was misled to request for funding from the state government under the guise of “hardship allowance”
In the statement made to the ICPC exclusively obtained by Vanguard, an apparently remorseful Sulieman said, “this is an experience, especially the inappropriate use of the word “hardship allowance” I will never forget in my life. I am sincerely sorry about it.”
He admitted that, the money collected from the state government was not the normal allowances paid by INEC, saying, “The allowances we collected and shared were not the normal allowances.
Speculations that, the minister may have asked to leave the Federal Cabinet on account of the allegations could not be confirmed as he reported for work yesterday, with no indications that he was set to quit office.
The Head of Information and Public Affairs in the ICPC, Mr Mike Sowe, also said, the anti-graft body is not statutorily bound to write the Presidency about Sulieman’s matter, saying, “ it is not our right to write to the Presidency, if we do that, it means we do not know our job. It is not in the Act”.
Presidential spokesman Ima Niboro in response to a text message ruled out speculations that the embattled Minister had been asked to remain in the cabinet until the end of his trial.
In 2008, Prof. Adenike Grange the then Minister of Health was reportedly compelled to resign before she was prosecuted among other senior officials of the Ministry over disbursement of the unspent 2007 budget of the Ministry. She was, however, eventually acquitted of the allegations filed against her by the Economic and Financial Crimes Commission.
http://www.vanguardngr.com/2011/01/uncertainty-clouds-minister%E2%80%99s-stay-in-cabinet-ahead-of-trial/#
http://www.prolongpharmaceuticals.com/ota.htm
Prolong Pharmaceuticals Leases 24,000-Square-Foot Manufacturing Facility, Adds Facilities Veteran to Executive Team
Dr. Hemant Misra Joins Prolong as VP, Manufacturing and Facilities Operations
SOUTH PLAINFIELD, N.J., Jan. 25, 2011 /PRNewswire/ -- Prolong Pharmaceuticals, which in October secured a $30 million funding commitment from a private investment group, today announced the signing of a long term lease on a manufacturing facility in South Plainfield, New Jersey and the formal addition of Dr. Hemant Misra to the Prolong Executive Management team as Vice President, Manufacturing and Facilities Operations.
The manufacturing facility has been used by Prolong since early 2010, and has already produced clinical batches of Prolong's oxygen transfer agent, SANGUINATE™, sufficient to take the company through the Phase I and II trials expected to begin this year. "Through this agreement we are able to take tens of millions of dollars and years of time off our product development cycle," said Prolong President Glenn Kazo. "We are already producing large scale biological product in a cGMP environment, and now is the right time to secure our longer term manufacturing facilities. Our fortune in teaming with Hemant and acquiring this particular facility at this time in our corporate history is quite remarkable."
A 30-year veteran of the pharmaceutical industry, Dr. Misra will head the process of bringing the new facility to full capacity. Prior to joining Prolong, Dr. Misra managed manufacturing operations, drug development and clinical studies for XTL Biopharmaceuticals as Vice President. His work has also included management roles as the Director of Clinical Drug Development and Corporate Development at Genzyme Transgenics, a subsidiary of Genzyme Corporation. Previously, Hemant held senior level positions at Activecyte, Inc., a Boston Consulting Group Company, at Chemsyn Science Labs and at Andrulis Pharmaceuticals.
Dr. Misra joins a team of industry leaders which has been assembled at Prolong. In addition to CEO and Scientific Founder Dr. Abraham Abuchowski, Prolong has named Glenn Kazo as President, brought aboard Richard Prince as Vice President, Quality, and added Andy Burger as Vice President, Information Services.
About Prolong Pharmaceuticals
Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC is developing biopharmaceutical products targeting the treatment of anemia resulting from an oxygen deficiency. First founded in 2002 as a research company, Prolong is focused on sickle cell anemia, diabetic ischemia, and several trauma indications. The company's senior management team includes inventors of the most successful drug delivery technology in pharmaceutical history, PEGylation, now responsible for more than $30 billion in drug sales worldwide. In October 2010, Prolong secured a $30 million funding commitment from a private investor group. For more information visit: www.prolongpharmaceuticals.com
http://www.prnewswire.com/news-releases/prolong-pharmaceuticals-leases-24000-square-foot-manufacturing-facility-adds-facilities-veteran-to-executive-team-114577619.html